Briefing
723O Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients: Final results of the PEGASUS trial
Among patients with two consecutive post-surgical negative tests, 12 relapses occurred, for a 2-year no-evidence-of-disease rate of 88% (90% CI 81-93). The predefined feasibility threshold (fewer than 14 relapses among 134 negative patients to exclude 85% in favor of 92%) was not met, though the point estimate exceeded 85%. In the 35 positive patients, 13 (37%) relapsed; 2-year time-to-relapse was 87.6% vs 61.5% (HR 3.22, P=0.0013).
- Design: oral
- n: 135 patients (100 liquid-biopsy-negative, 35 positive); median follow-up 33.5 months
- Assay: Guardant Reveal (v L1.2)